NCT01458535View on ClinicalTrials.gov

A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Hepatitis C Virus
Interventions
DRUG

ABT-450

tablets

DRUG

ABT-267

tablets

DRUG

ribavirin

tablets

DRUG

ritonavir

capsules

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01458535 - A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) | Biotech Hunter | Biotech Hunter